Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Endothelial Response to Blood-Brain Barrier Disruption in the Human Brain.
Gould A, Luan Y, Hou Y, Korobova FV, Chen L, Arrieta VA, Amidei C, Ward R, Gomez C, Castro B, Habashy K, Zhang D, Youngblood M, Dmello C, Bebawy J, Bouchoux G, Stupp R, Canney M, Yue F, Iruela-Arispe ML, Sonabend AM. Gould A, et al. Among authors: sonabend am. JCI Insight. 2024 Dec 26:e187328. doi: 10.1172/jci.insight.187328. Online ahead of print. JCI Insight. 2024. PMID: 39724015 Free article.
Phase II trial of blood-brain barrier permeable peptide-paclitaxel conjugate ANG1005 in patients with recurrent high-grade glioma.
Dmello C, Brenner A, Piccioni D, Wen PY, Drappatz J, Mrugala M, Lewis LD, Schiff D, Fadul CE, Chamberlain M, Kesari S, Ahluwalia M, Ghosh D, Sonabend AM, Kumthekar P. Dmello C, et al. Among authors: sonabend am. Neurooncol Adv. 2024 Dec 14;6(1):vdae186. doi: 10.1093/noajnl/vdae186. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 39713041 Free PMC article.
Targeting ZNF638 activates antiviral immune responses and potentiates immune checkpoint inhibition in glioblastoma.
Seetharam D, Chandar J, Ramsoomair CK, Desgraves JF, Medina AA, Hudson AJ, Amidei A, Castro JR, Govindarajan V, Wang S, Zhang Y, Sonabend AM, Valdez MJM, Maric D, Govindarajan V, Rivas SR, Lu VM, Tiwari R, Sharifi N, Thomas E, Alexander M, DeMarino C, Johnson K, De La Fuente MI, Nasany RA, Noviello TMR, Ivan ME, Komotar RJ, Iavarone A, Nath A, Heiss J, Ceccarelli M, Chiappinelli KB, Figueroa ME, Bayik D, Shah AH. Seetharam D, et al. Among authors: sonabend am. bioRxiv [Preprint]. 2024 Oct 15:2024.10.13.618076. doi: 10.1101/2024.10.13.618076. bioRxiv. 2024. PMID: 39464150 Free PMC article. Preprint.
THOC1 complexes with SIN3A to regulate R-loops and promote glioblastoma progression.
Budhiraja S, Baisiwala S, Cho S, Chojak R, Kazi HA, Stepniak A, Perrault EN, Chen L, Park CH, Dmello C, Lin P, Sonabend AM, Ahmed AU. Budhiraja S, et al. Among authors: sonabend am. bioRxiv [Preprint]. 2024 Sep 26:2024.09.24.614748. doi: 10.1101/2024.09.24.614748. bioRxiv. 2024. PMID: 39386597 Free PMC article. Preprint.
MAPK/ERK signaling in gliomas modulates interferon responses, T cell recruitment, microglia phenotype, and immune checkpoint blockade efficacy.
Kim KS, Zhang J, Arrieta VA, Dmello C, Grabis E, Habashy K, Duffy J, Zhao J, Gould A, Chen L, Hu J, Balyasnikova I, Chand D, Levey D, Canoll P, Zhao W, Sims PA, Rabadan R, Pandey S, Zhang B, Lee-Chang C, Heiland DH, Sonabend AM. Kim KS, et al. Among authors: sonabend am. bioRxiv [Preprint]. 2024 Sep 18:2024.09.11.612571. doi: 10.1101/2024.09.11.612571. bioRxiv. 2024. PMID: 39345374 Free PMC article. Preprint.
B cell-based therapy produces antibodies that inhibit glioblastoma growth.
Wang S, Castro BA, Katz JL, Arrieta V, Najem H, Vazquez-Cervantes GI, Wan H, Olson IE, Hou D, Dapash M, Billingham LK, Chia TY, Wei C, Rashidi A, Platanias LC, McCortney K, Horbinski CM, Stupp R, Zhang P, Ahmed AU, Sonabend AM, Heimberger AB, Lesniak MS, Riviere-Cazaux C, Burns T, Miska J, Fischietti M, Lee-Chang C. Wang S, et al. Among authors: sonabend am. J Clin Invest. 2024 Aug 29;134(20):e177384. doi: 10.1172/JCI177384. J Clin Invest. 2024. PMID: 39207859 Free PMC article.
Pediatric glioma immune profiling identifies TIM3 as a therapeutic target in BRAF fusion pilocytic astrocytoma.
Tripathi S, Najem H, Dussold C, Pacheco S, Du R, Sooreshjani M, Hurley L, Chandler JP, Stupp R, Sonabend AM, Horbinski CM, Lukas RV, Xiu J, Lopez G, Nicolaides TP, Brown V, Wadhwani NR, Lam SK, James CD, Rao G, Castro MG, Heimberger AB, DeCuypere M. Tripathi S, et al. Among authors: sonabend am. J Clin Invest. 2024 Aug 13;134(19):e177413. doi: 10.1172/JCI177413. J Clin Invest. 2024. PMID: 39137048 Free PMC article.
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomas.
Kim KS, Habashy K, Gould A, Zhao J, Najem H, Amidei C, Saganty R, Arrieta VA, Dmello C, Chen L, Zhang DY, Castro B, Billingham L, Levey D, Huber O, Marques M, Savitsky DA, Morin BM, Muzzio M, Canney M, Horbinski C, Zhang P, Miska J, Padney S, Zhang B, Rabadan R, Phillips JJ, Butowski N, Heimberger AB, Hu J, Stupp R, Chand D, Lee-Chang C, Sonabend AM. Kim KS, et al. Among authors: sonabend am. Neuro Oncol. 2024 Nov 4;26(11):2044-2060. doi: 10.1093/neuonc/noae135. Neuro Oncol. 2024. PMID: 39028616
135 results